KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cme (CME) Cash & Equivalents (2016 - 2026)

Cme has reported Cash & Equivalents over the past 18 years, most recently at $2.4 billion for Q1 2026.

  • Quarterly Cash & Equivalents rose 70.16% to $2.4 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.4 billion through Mar 2026, up 70.16% year-over-year, with the annual reading at $4.4 billion for FY2025, 52.71% up from the prior year.
  • Cash & Equivalents was $2.4 billion for Q1 2026 at Cme, down from $4.4 billion in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $4.4 billion in Q4 2025 and troughed at $1.4 billion in Q1 2025.
  • The 5-year median for Cash & Equivalents is $2.1 billion (2022), against an average of $2.3 billion.
  • Biggest five-year swings in Cash & Equivalents: surged 118.46% in 2022 and later fell 23.49% in 2023.
  • Tracing CME's Cash & Equivalents over 5 years: stood at $2.7 billion in 2022, then rose by 7.05% to $2.9 billion in 2023, then fell by 0.67% to $2.9 billion in 2024, then surged by 52.71% to $4.4 billion in 2025, then tumbled by 45.86% to $2.4 billion in 2026.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $2.4 billion, $4.4 billion, and $2.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.